Agenus - Stock Price History | AGEN

Historical daily share price chart and data for Agenus since 2021 adjusted for splits. The latest closing stock price for Agenus as of October 15, 2021 is 5.31.
  • The all-time high Agenus stock closing price was 315.72 on March 09, 2000.
  • The Agenus 52-week high stock price is 6.79, which is 27.9% above the current share price.
  • The Agenus 52-week low stock price is 2.50, which is 52.9% below the current share price.
  • The average Agenus stock price for the last 52 weeks is 4.33.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Agenus Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 3.5027 4.0400 5.2000 1.9200 3.1800 -21.87%
2019 3.0215 2.5100 4.4000 2.1700 4.0700 71.01%
2018 3.0122 3.5400 6.0400 1.5900 2.3800 -26.99%
2017 3.9090 4.1600 5.3700 3.2400 3.2600 -20.87%
2016 4.5745 4.4600 7.3600 2.7200 4.1200 -9.25%
2015 6.1392 3.9800 9.7800 3.8800 4.5400 14.36%
2014 3.2013 2.7800 5.1000 2.4100 3.9700 50.38%
2013 3.6174 4.2400 4.9300 2.4000 2.6400 -35.61%
2012 4.6131 2.1700 7.0400 2.1000 4.1000 105.00%
2011 4.3567 6.3587 6.6587 2.0000 2.0000 -66.99%
2010 5.3949 3.8548 8.2783 3.5999 6.0588 57.81%
2009 7.1490 2.8794 17.9364 1.7996 3.8392 33.33%
2008 10.4890 12.4775 18.1764 2.4595 2.8794 -76.47%
2007 14.9737 11.5177 26.5747 9.4181 12.2376 11.48%
2006 16.6463 28.7343 41.4517 9.2382 10.9778 -61.55%
2005 37.7835 59.9880 59.9880 28.5543 28.5543 -52.96%
2004 51.7600 68.7463 73.0654 28.3143 60.7079 -10.76%
2003 66.5418 64.1872 94.7810 42.7714 68.0264 10.74%
2002 65.3403 92.9214 100.9598 41.1578 61.4277 -37.56%
2001 95.8749 66.3467 120.5759 64.4871 98.3803 48.28%
2000 117.9615 277.4445 315.7169 63.7672 66.3467 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.238B $0.088B
Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00